Navigation Links
Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care

e. Patients received ACTEMRA(TM) intravenously (either 4mg/kg or 8mg/kg) every 4 weeks plus methotrexate weekly, or placebo infusions plus methotrexate weekly, for 24 weeks. The study enrolled patients at 73 trial sites in 17 countries outside the United States, and is one of five Phase III trials designed to study ACTEMRA(TM) as a potential new treatment for RA.

Data from the study were analyzed to determine patients' response to treatment by using three standard assessments: ACR score(1), developed by the of Rheumatology (ACR), DAS28(2), a measurement of RA disease activity, and EULAR(3), a measurement of treatment response.

In the study, 43.9% of patients treated with ACTEMRA(TM) (8mg/kg) plus methotrexate achieved at least a 50% (ACR50) reduction in symptoms compared to 10.8% of patients receiving placebo and methotrexate; ACR70 was achieved in 22% of the treatment group versus 2% in the control group. At 24 weeks, disease remission, as measured by DAS28 (<2.6), was achieved by 28% of patients treated with ACTEMRA(TM) 8mg/kg plus methotrexate compared to 1% of those in the placebo and methotrexate group. At 24 weeks, the difference in the reduction of DAS28 from baseline was greater and statistically significant (p<0.0001) in patients treated with ACTEMRA(TM) 8mg/kg plus methotrexate (-3.43) compared to those in the placebo and methotrexate group (-1.55). According to the EULAR response, a good/moderate response was seen in 79.5% and 61.9% of patients receiving ACTEMRA(TM) plus methotrexate 8mg/kg and 4mg/kg, respectively, compared to 34.8% of patients receiving placebo plus methotrexate.

About ACTEMRA(TM) (tocilizumab)

ACTEMRA(TM) is the first humanized interleukin-6 (IL-6) receptor- inhibiting monoclonal antibody studied for the treatment of RA. Roche and Chugai have initiated a collaborative Phase III clinical development program in RA that is underway outside Japan with more than 4,000 patients have been recruited in 41 countries
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
2. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
3. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
6. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
7. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
8. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
9. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers of ... bamboo deckings . Moreover, the company has launched a ... available at deeply discounted rates. , As is ... the significance of online business nowadays. Thus, BambooIndustry.com pays ... workers are striving to deliver both value and efficiency ...
(Date:10/19/2014)... Having been working in the garment industry for decades, ... According to James, one of the company’s top designers, many ... high-low skirts that add beauty to them. Chiffon floor length ... unveiled its new selection of 2014 long prom dresses. ... items are available in over 20 popular designs. The company ...
(Date:10/19/2014)... 2014 SweetDressy.com, a professional company of ... promotion for long evening dresses . All the ... offer; the current discount is up to 66 percent ... pioneers in the fashion field. Its dress specialists are ... in various parts of the world. All the company’s ...
(Date:10/19/2014)... Oct. 19, 2014 (HealthDay News) -- New stem cell-based ... lead to new treatments, a new study suggests. ... human intestinal tissue in a lab dish. They then ... for studying intestinal disorders, according to the researchers. ... diseases and conditions that can cause intestinal failure, from ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... that the actress' current rehab spell will bring a stop ... incidents . ,As the Mean Girls star checked ... 28, after being arrested for DUI, her supposed friends got ... ,One friend told America's Star magazine that Lohan attempted to ...
... Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. ... and Drug Administration (FDA) for its Abbreviated ... Tablets, 12.5 mg and 25 mg. ,Mylan's ... June 29, 2007, concurrent with the expiration of ...
... the explosive growth of smoke-free air laws worldwide ... now protected by laws that require smoke-free air in ... momentum behind smoke-free air laws will continue accelerating because ... to protect the public from secondhand smoke. ...
... announced today the presentation of new analysis of data ... on the clinical development of their investigational drug, Viprinex(TM) ... the 16th annual European Stroke Congress in Glasgow, Scotland ... derived from the venom of the Malayan pit viper. ...
... our nation, Americans are very optimistic about the war ... nationwide survey sponsored by Abbott, nearly two-thirds (64%) believe ... ,"As an organization researching new options to ... will live up to the optimism expressed by Americans ...
... global public health community observes World No Tobacco Day, the ... epidemic that tobacco causes for our nation. Two important new ... can address the deadly toll of tobacco -- especially secondhand ... Tobacco Day. ,The Institute of Medicine, the group ...
Cached Medicine News:Health News:Growth of Smoke-Free Air Laws Worldwide; More Than 200 Million Found "Fully Protected" 2Health News:Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke 2Health News:Americans Optimistic About the War on Cancer 2Health News:World No Tobacco Day Focuses on Secondhand Smoke 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: